The role of Rixubis™ in the treatment of hemophilia B.

Hemophilia B is an inherited coagulopathy caused by the partial or complete deficiency of factor (F) IX. Factor replacement therapy, involving the intravenous infusion of plasma-derived or recombinant (r) FIX concentrate, is the cornerstone of treatment, used to control and prevent bleeding episodes. Although several plasma-derived FIX products are available, until recently, only a single rFIX concentrate was on the market. The aim of this paper is to review the pharmacokinetics, hemostatic efficacy, and safety of Rixubis™ (Baxter Healthcare Corporation, CA, USA), a newly licensed rFIX product.